Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
lineage cell therapeutics股价下跌，因公司宣布最多6600万美元的注册直接发行定价。此外，D Boral Capital表示维持买入评级，将股票的目标价从3美元降至2美元。
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Lineage cell therapeutics的股票在公司宣布高达6600万注册直接发行的定价后交易下跌。此外，D Boral Capital维持对该股票的买入评级，并将其目标价从3美元下调至2美元。
资讯热榜
更新时间